UK universities launch 4D medical device manufacturing project
Researchers from the UK's University of Birmingham and Imperial College London have launched a new 4D medical device manufacturing project.
The 4D Health Tech initiative seeks to fill a crucial gap in traditional medical device manufacturing design processes by incorporating factors such as growth, movement, and tissue regeneration or degeneration, which are often overlooked.
The project will promote the use of materials that degrade predictably and promote faster healing, and combine this ethos with automated design, advanced manufacturing processes, and patient specific pre-clinical testing – which is expected to result in 'better' medical devices that cater to more diverse patient populations.
Backed by £1.2m in funding from the UK Research and Innovation's (UKRI) Engineering and Physical Sciences Research Council (EPSRC), the three-year project will create Network Plus, an initiative intended to connect academics, businesses, clinicians, patients, and policymakers, serving as a conduit towards the creation of bigger, longer-term research projects in the field.
The project funding is part of a broader £10m package allocated by EPSRC across the UK's manufacturing sector to respond to Tomorrow's Engineering Research Challenges, a paper the UKRI published in 2022. Concerning medical device and equipment manufacturing, the paper highlights the importance of a re-manufacturing and re-use approach to ensure sustainability in manufacturing for the sector to support a move towards the principles of a circular economy.
According to Dr Sophie Cox, associate professor in healthcare technologies at Birmingham University's School of Chemical Engineering, medical devices designed to replace or repair our bodies typically neglect the dimension of time, a reality that compromises their function and lifespan.
'Our vision is to transform the way we engineer medical devices,' said Dr Cox.
'Fostering connections across the supply chain will create a new culture of 4D Health Tech embedding innovative thinking, patient perspective and diversity – ensuring this new age of medical devices offers improved healthcare outcomes for everyone.'
In related manufacturing developments in the medical device sector, companies are ramping up their investment in 3D printing for the creation of custom prosthetics, implants and surgical tools that meet the individual needs of patients. According to GlobalData analysis, the medical 3D printing market is growing at a CAGR of 21% and forecast to reach a valuation of $4bn in 2026, up from $2bn in 2022.
"UK universities launch 4D medical device manufacturing project" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Penumbra may gain market share in peripheral embolisation coils with Ruby XL
Penumbra has announced US Food and Drug Administration approval for its Ruby XL system, which includes three coils: the Ruby XL, the POD XL and the Packing Coil XL. The Ruby XL coil is a device used in vascular embolisation, a procedure to block or close off blood vessels, and can be used to frame large aneurysms, while the POD XL is designed for use in high-flow vessels and the Packing Coil XL is designed to adjust to the shape of any vessel up to 70cm in length. All Ruby XL system coils can be delivered through a 0.035-inch diagnostic catheter. The system is expected to enable Penumbra to increase its market share in peripheral embolisation coils, according to leading data and analytics company GlobalData. According to GlobalData's US healthcare facility invoicing database, Penumbra currently holds the majority market share for peripheral embolisation coils. Its new coil system allows for peripheral embolisation procedures to be done on a wider range of aneurysm sizes and in longer vessels. If the Ruby XL coil is widely adopted by physicians, Penumbra may be able to capture half the entire market. The approval of the new coil could put a bigger gap between Penumbra and its competitors in the market. Physicians may choose Ruby XL coils for their procedures in order to gain better control of large aneurysms. The Ruby XL system may come with cost savings for consumers as it delivers more volume per coil than other available coils. The average selling price (ASP) of these coils ranges from approximately $900 to $2,000. Already in the middle of this range with its current coils, Penumbra has a competitive advantage for new products. If they come in with a competitive ASP, Penumbra may displace competitor coils for relevant procedures. Penumbra stands to maintain its market lead and possibly increase its market share as the purchasing of the Ruby XL system begins. GlobalData will continue to monitor market trends as purchasing picks up. It is expected that facilities will begin purchasing these coils in June 2025. "Penumbra may gain market share in peripheral embolisation coils with Ruby XL" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Philips launches new point-of-care ultrasound system
Philips has launched a new point-of-care (POC) ultrasound system designed to broaden the accessibility of ultrasound for diagnostic and therapeutic interventions. The Flash 5100 POC system is applicable for use cases in anaesthesia, critical care, emergency medicine, and musculoskeletal imaging. The system is built on Philips' existing cardiology and general imaging ultrasound technology. Philips describes the system as utilising an 'encounter-based' workflow, allowing clinicians to perform and document exams in real time. According to the company, this makes the new system best placed for use in high-pressure environments such as the emergency room (ER) and trauma units. Following Philips' recent Future Health Index 2025 report, which revealed that 33% of patients surveyed have experienced worsening health due to delays in seeing a doctor, with one in four patients ending up in hospital due to long wait times, the company noted that POC ultrasound is becoming increasingly vital. Jeff Cohen, global business leader of ultrasound at Philips, said the new system represents a 'major leap forward' in Philips' commitment to the POC ultrasound segment, with the system joining Philips' portfolio. This includes its app-based Lumify ultrasound system, which received 510(k) clearance from the US Food and Drug Administration (FDA) in 2015. 'Designed for speed, mobility, and precision, the Flash 5100 empowers clinicians to make confident, real-time decisions in the most urgent settings – at the bedside, in the ICU, the emergency department, or the OR [operating room],' Cohen said. The Flash 5100 is also designed to support Philips' tele-ultrasound solution, Collaboration Live, in which clinicians can connect with remote colleagues in real-time to share images and guidance. 'In today's overburdened clinical landscape, that kind of remote collaboration isn't just helpful – it's essential,' Cohen added. According to Ashley Clarke, senior healthcare analyst at GlobalData, POC ultrasound devices in the US currently have an annual growth rate of around 3.75%. Representing one of the highest uptake rates of ultrasound among healthcare systems and clinics in the US, Clarke said that the figure is primarily driven by the fact that POC ultrasound systems cost between $5,000 and $20,000 on average, whereas traditional ultrasound systems may cost anywhere from $50,000 to $200,000. A market model by GlobalData forecasts that the handheld ultrasound market, of which POC ultrasound systems are a part, will reach a valuation of around $43.3bn by 2034, up from $29.2bn in 2024. "Philips launches new point-of-care ultrasound system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
5 days ago
- Forbes
The UK Must Bridge Funding Gaps To Position Itself As Hub For R&D
Innovation needs a new safe haven and while the UK has all the building blocks to be that place, to make it happen we need to ensure that our ambition translates into delivery. The UK's latest research and development funding settlement has reignited a familiar tension of long-term ambition versus short-term constraint. CaSE has cautioned that the government's £8.8 billion funding allocation to UK Research and Innovation (UKRI) essentially amounts to a flat-cash settlement. Along with inflation and rising operating costs this means less room for new investment – forcing harder choices at a time when our ambitions to become a global hotspot for science depend on sustained momentum. The recent announcement of 10-year budgets for R&D funding is a welcome signal of long-term intent and offers a degree of clarity that industry and academia alike have long called for. However, visibility alone is not the same as increased investment. Unless these budgets translate into real-terms growth, the UK risks falling behind its global competitors. However, disruption in the global R&D landscape and notably the US, presents an opportunity. If we act swiftly and work strategically, the UK can position itself as a stable, globally attractive home for international talent and industry investment. But this must be matched by real-world readiness. Preparing for change In the US, proposals to significantly reduce budgets for key agencies like the National Institute of Health and National Science Foundation have raised alarm. Coupled with a rise in anti-vaccine rhetoric and scientists facing budget-cuts overnight, we're seeing an environment emerge that may stifle talent rather than nurture it. I – and many others – will also be keeping an ear to the ground as we continue to await a decision around pharma tariffs. While we're not expecting a mass exodus out of the US, it would be naïve to think that in this climate, talent couldn't be tempted elsewhere. To attract these internationally mobile innovators, tech entrepreneurs, engineers and scientists, we need to prove that the welcome mat is out, and the funding tap is on. That's where innovation clusters can play a vital role. Back in 2021, QIAGEN, a global diagnostics company from Germany, established its Global Centre of Excellence for Precision Medicine at Bruntwood SciTech's Citylabs 2.0, where it now actively partners with the NHS to accelerate healthcare breakthroughs. More recently, US pharmaceutical giant Eli Lilly began a five-year trial into the effectiveness of weight loss drug Tirzepatide on the job prospects of people living with obesity in Greater Manchester. The trial is being run by Health Innovation Manchester in partnership with Eli Lilly, along with the University of Manchester and local digital trials company NorthWest EHealth. And at a time when commercial clinical trial recruitment is in decline, Greater Manchester is bucking the trend, driven by a good relationship with the patient population, strong research infrastructure, a talented workforce and collaboration between providers, businesses, academia and industry. That is to say, while the national funding picture remains tight, we're seeing regional hubs across the UK stepping up. Regional strength equals international advantage A well-known challenge for new start-ups, especially within technology and innovation, is attracting early-stage investment. We need to see improved funding in areas away from the more traditional locations of London and South East England, that can attract young companies and new talent – both nationally and internationally. As such, we welcome the Government's latest commitment to provide £500 million for regions across the UK to make decisions around how to boost R&D in a way that is most appropriate for them. Innovation hubs in cities like Manchester, Birmingham and Leeds are helping to maintain momentum despite national funding pressures. These places are building internationally connected clusters underpinned by strong partnerships between academia, industry and the public sector. In Manchester, for example, the recently opened Citylabs 4.0 provides new specialist lab and office space on Europe's largest clinical-academic campus, supporting life sciences research and strengthening collaboration with the NHS. Meanwhile, in Leeds, a wave of activity is strengthening the city's profile as a destination for innovative, high-growth businesses. Iconic British broadcaster Channel 4, Yorkshire Bank and international energy and services company Centrica all have significant operations in the city, attracted by its growing financial services cluster, collaborative tech ecosystem and access to skilled talent. However, we're seeing competition across the EU to attract internationally mobile talent and businesses in the sector. The European Commission recently unveiled its 'Choose Europe' scheme to promote the region as a world-leading centre of research, innovation and scientific freedom – including a €500 million pledge for 2025-27, to make Europe a 'magnet' for researchers. To draw top-tier talent and investment then, we need to double-down on what makes the UK standout. That is, openness to collaboration, strength in diversity of research and a unique blend of regionally driven infrastructure and ecosystem support. The government's commitment to UKRI is a signal of ambition but flat cash won't be enough to stay ahead. If we're serious about being a superpower of tech, innovation and science, now is the time to act. That means ensuring real-term investment to support our regional powerhouses and showing the world that we are the most attractive, stable home for the next generation of global innovation.
